Literature DB >> 3497030

T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta.

M Wrann, S Bodmer, R de Martin, C Siepl, R Hofer-Warbinek, K Frei, E Hofer, A Fontana.   

Abstract

T cell suppressor factor produced by human glioblastoma cells inhibits T cell proliferation in vitro and more specifically interferes with interleukin-2 (IL-2)-dependent T cell growth. Here we report the purification of this factor from conditioned medium of the human glioblastoma cell line 308. Amino-terminal sequence analysis of the 12.5-kd protein demonstrates that eight out of the first 20 amino acids are identical to human transforming growth factor-beta. Purified glioblastoma-derived T cell suppressor factor and transforming growth factor-beta from porcine platelets inhibit both IL-2-induced proliferation of ovalbumin-specific T helper cells and lectin-induced thymocyte proliferation with similar specific activities. If released by glioblastoma cells in vivo, the factor may contribute to impaired immunosurveillance and to the cellular immunodeficiency state detected in the patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3497030      PMCID: PMC553535          DOI: 10.1002/j.1460-2075.1987.tb02411.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  24 in total

1.  Specificity of lymphocyte-mediated cytotoxicity in patients with primary intracranial tumors.

Authors:  N L Levy
Journal:  J Immunol       Date:  1978-09       Impact factor: 5.422

2.  Immunobiology of primary intracranial tumors. Part 3: Microcytotoxicity assays of specific immune responses of brain tumor patients.

Authors:  R E Woosley; M S Mahaley; J L Mahaley; G M Miller; W H Brooks
Journal:  J Neurosurg       Date:  1977-12       Impact factor: 5.115

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Ultrasensitive stain for proteins in polyacrylamide gels shows regional variation in cerebrospinal fluid proteins.

Authors:  C R Merril; D Goldman; S A Sedman; M H Ebert
Journal:  Science       Date:  1981-03-27       Impact factor: 47.728

5.  Identification of the phenylthiohydantoin derivatives of amino acids by high pressure liquid chromatography, using a ternary, isocratic solvent system.

Authors:  F Lottspeich
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1980-12

6.  Letter: Impaired cell-mediated immunity in human brain tumours.

Authors:  D G Thomas; C B Lannigan; P O Behan
Journal:  Lancet       Date:  1975-06-21       Impact factor: 79.321

7.  Serological analysis of cell surface antigens of malignant human brain tumors.

Authors:  M Pfreundschuh; H Shiku; T Takahashi; R Ueda; J Ransohoff; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

8.  Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours.

Authors:  T L Roszman; W H Brooks
Journal:  Clin Exp Immunol       Date:  1980-02       Impact factor: 4.330

9.  A transcript from a Drosophila pattern gene predicts a protein homologous to the transforming growth factor-beta family.

Authors:  R W Padgett; R D St Johnston; W M Gelbart
Journal:  Nature       Date:  1987 Jan 1-7       Impact factor: 49.962

10.  Autologous humoral response to human gliomas and analysis of certain cell surface antigens: in vitro study with the use of microcytotoxicity and immune adherence assays.

Authors:  H B Coakham; P L Kornblith; E A Quindlen; L A Pollock; W C Wood; L C Hartnett
Journal:  J Natl Cancer Inst       Date:  1980-02       Impact factor: 13.506

View more
  77 in total

1.  Transforming growth factor-ßs as modulators of pericellular proteolytic events.

Authors:  J Keski-Oja; J Lohi; M Laiho
Journal:  Cytotechnology       Date:  1989-12       Impact factor: 2.058

Review 2.  TGF-beta: problems and prospects.

Authors:  M B Sporn; A B Roberts
Journal:  Cell Regul       Date:  1990-11

3.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

Review 4.  Contact dermatitis. Clinical perspectives and basic mechanisms.

Authors:  A Nasir; A A Gaspari
Journal:  Clin Rev Allergy Immunol       Date:  1996       Impact factor: 8.667

Review 5.  Current challenges in designing GBM trials for immunotherapy.

Authors:  Shiao-Pei Weathers; Mark R Gilbert
Journal:  J Neurooncol       Date:  2015-01-11       Impact factor: 4.130

6.  TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity.

Authors:  E A Grimm; W L Crump; A Durett; J P Hester; S Lagoo-Deenadalayan; L B Owen-Schaub
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression.

Authors:  J A Reed; N S McNutt; V G Prieto; A P Albino
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

8.  Transforming growth factor-beta2 is a molecular determinant for site-specific melanoma metastasis in the brain.

Authors:  Chenyu Zhang; Fahao Zhang; Rachel Tsan; Isaiah J Fidler
Journal:  Cancer Res       Date:  2009-01-13       Impact factor: 12.701

9.  Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype.

Authors:  E A Grimm; J M Bruner; J Carinhas; J A Köppen; W G Loudon; L Owen-Schaub; P A Steck; R P Moser
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

10.  Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial.

Authors:  R E Merchant; D W McVicar; L H Merchant; H F Young
Journal:  J Neurooncol       Date:  1992-01       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.